Ma En-Guang, Bai Yu-Feng, Cao Wei, Cao Yan, Huang Yong-Gang, Cheng Huan-Chen, An Rui-Hua
The Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, China.
The Department of Urology Surgery, The First Hospital of Harbin, Harbin, China.
Oncotarget. 2017 Jul 7;8(38):63780-63787. doi: 10.18632/oncotarget.19070. eCollection 2017 Sep 8.
Cytosine5-hyxymethylation (5hmC)which is a new epigenetic modification form plays important roles in the development and progression of tumors. In the present study, we observed that levels of 5hmC in the promoter region of Von Hippel-Lindau (VHL) were lower in 97 samples of renal clear cell carcinoma tissue than in matched adjacent benign tissues. Moreover, when the cancer tissue samples were divided based on pathological staging, VHL expression and the level of 5hmC in the VHL promoter were both lower in pathological grade III tumors than in grades I or II. Correspondingly, expression of TET1, which catalyzes the formation of 5hmC, was also lower in grade III renal clear cell carcinomas than in grade I or II disease. These findings suggest the 5hmC level on VHL is a key determinant of the gene's expression and may participate in the occurrence and development of renal clear cell carcinoma. Thus the 5hmC level may be a useful indicator for early diagnosis and appropriate treatment of renal clear cell carcinoma.
5-羟甲基胞嘧啶（5hmC）是一种新的表观遗传修饰形式，在肿瘤的发生和发展中起着重要作用。在本研究中，我们观察到97例肾透明细胞癌组织样本中，冯·希佩尔-林道（VHL）基因启动子区域的5hmC水平低于匹配的相邻良性组织。此外，根据病理分期对癌组织样本进行划分时，Ⅲ级肿瘤中VHL的表达及VHL启动子区域的5hmC水平均低于Ⅰ级或Ⅱ级。相应地，催化5hmC形成的TET1在Ⅲ级肾透明细胞癌中的表达也低于Ⅰ级或Ⅱ级病变。这些发现表明，VHL上的5hmC水平是该基因表达的关键决定因素，可能参与肾透明细胞癌的发生和发展。因此，5hmC水平可能是肾透明细胞癌早期诊断和合理治疗的有用指标。
